Grant for cancer on chip

Grant for cancer on chip

Nikolas Gaio, Cinzia Silvestri and William Quiros Solano, 3 PhD’s at Delft University of Technology, have filed a patent regarding their microfluidic device.

Together with 4 other selected startups, their company Biond LC won the opportunity to participate in the Health Holland Life Sciences@Work venture challenge.
The winner will be announced at the Dutch Life Sciences Conference in Leiden and will receive 25,000 euros as well as much exposure at this large life sciences business conference.
In the past, the Biond LC team received a NanoNext valorisation grant of 100,000 euros. Their device was also considered the most promising business case of the 12StartUp event organized by Yes!Delft”

.
An hDMT team led by researcher Dik van Gent (Erasmus MC) has received a grant from the Dutch Cancer Foundation (KWF) and financed by the Alpe d’HuZes funding scheme. The project team will develop a cancer-on-chip device that allows relatively long term culturing of (breast) tumor tissue

The BIOND will support this initiative with its hardware solutions.

Project information

Title: Developing a validated Cancer-on-Chip prototype for personalized medicine

Description: Cancer is a very heterogeneous disease: many different types of tumors exist and even not all tumor cells in one tumor are the same. This is a big problem for clinical decision making. How should we treat each individual tumor and how exactly does the tumor react to such a treatment? These questions are difficult to address when the tumor is still inside the body, but could be answered more readily if we can grow the tissue outside the body, where we can image the tissue using microscopic techniques. Therefore, we aim to develop the technology to make this possible. The project brings together (medical) biologists, engineers and the company Genmab, who will work together on creating a working and validated ‘cancer-on-chip’ prototype that can be used in future projects for personalized medicine, as well as for asking fundamental questions about cancer biology. The project is unique in bringing together this expertise and it is high risk because it is difficult to predict what the optimal technological set up will be. However, the options for further research will be enormous if the project teams succeed in its endeavor.